Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
Two Sigma Advisers LP Takes Position in BioXcel Therapeutics Inc (NASDAQ:BTAI)
09:36am, Saturday, 03'rd Oct 2020
Two Sigma Advisers LP bought a new stake in shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) during the second quarter, according to the company in its most recent 13F filing with the Securities and E
BioXcel Therapeutics: Opportunity Emerges During Pandemic While Mental Health Is Being Ignored (NASDAQ:BTAI)
10:35pm, Wednesday, 23'rd Sep 2020
In 2020, the central nervous system (CNS) market has largely failed to keep up with $IBB. The current stock price of BioXcel Therapeutics is highly influenced by the approval and filing of the NDA for
Evogene: Hidden Gems Of Computational Predictive Biology: (Part 4 Of 4), Canonic Ltd. (Medical Cannabis) (NASDAQ:EVGN)
06:30pm, Wednesday, 23'rd Sep 2020
Despite its recent share price increase, Evogene continues to be undervalued given the sum of parts valuation of its 4 main subsidiaries and $45 million cash position.
BTAI: TRANQUILITY Trial Readout Possible in 4Q20…
10:02am, Monday, 17'th Aug 2020
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update TRANQUILITY Readout Possible in 4Q20 BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is currently conducting the Phase 1b/2
Why BioXcel Therapeutics Stock Is Down Today
04:34pm, Friday, 14'th Aug 2020
Shares of clinical-stage biotech BioXcel Therapeutics (NASDAQ: BTAI) are down by 9.9% as of 11:58 a.m. EDT on Friday, after the company released its second-quarter earnings report before the market op
BioXcel Therapeutics' (BTAI) CEO Vimal Mehta on Q2 2020 Results - Earnings Call Transcript
03:15pm, Friday, 14'th Aug 2020
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2020 Earnings Conference Call August 14, 2020 8:30 AM ET Company Participants Vimal Mehta – Chief Executive Officer Michael Stanton – Controller Rob Ris
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
11:00am, Friday, 14'th Aug 2020
SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (“NDA”) submission to U.S. Food and Drug Administration (“FDA”) planned for Q1 2021
BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and Webcast
11:00am, Friday, 07'th Aug 2020
NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence
BioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth Conference
11:00am, Thursday, 06'th Aug 2020
NEW HAVEN, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
12:20am, Wednesday, 29'th Jul 2020
NEW HAVEN, Conn., July 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
08:21pm, Monday, 27'th Jul 2020
NEW HAVEN, Conn., July 27, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
12:00am, Sunday, 26'th Jul 2020
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
BTAI: Positive Results in SERENITY Trials Puts NDA Filing on Track for 1Q21…
09:45am, Wednesday, 22'nd Jul 2020
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Positive Results in Phase 3 SERENITY Trials On July 20, 2020, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced positive results fro
Bioxcel Therapeutics Hits Record On Bullish Test Results In Schizophrenia
08:33pm, Monday, 20'th Jul 2020
Bioxcel Therapeutics unveiled bullish Phase 3 results for an agitation treatment in patients with schizophrenia and bipolar disorder Monday — pushing BTAI stock to a record high.
